As described in APAC’s Briefing Document, this is a treatment “to reduce the incidence and severity of allergic reactions, including anaphylaxis after accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.”
The drug, called Palforzia, was designed by biotech company Aimmune Therapeutics.
